Decreased Heart Rate Variability in COVID-19
A B S T R A C T
On March 12, 2020, the World Health Organization (WHO) announced that the coronavirus disease 2019 (COVID-19) outbreak had become a pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to Angiotensin-Converting Enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed, not only in the lungs but also in the cardiovascular system. Therefore, SARS-CoV-2 can also damage the myocardium. We analysed three COVID-19 cases that resulted in death and found that either COVID-19 or antiviral drugs could affect the coupling between the autonomic nervous system and the sinus node, thus affecting heart rate variability and preventing the heart rate from rising in response to the increase in body temperature. Early detection of the preclinical phase of cardiac autonomic dysfunction may help determine patients in need of aggressive treatment and control of cardiovascular risk factors. Antiviral drugs should be used with caution in patients with heart injury.
Keywords
The coronavirus disease 2019, angiotensin-converting enzyme 2, heart rate variability, severe acute respiratory syndrome coronavirus 2
Get access to the full version of this article.
Article Info
Article Type
Case Report and Review of the LiteraturePublication history
Received: Thu 07, Oct 2021Accepted: Sat 23, Oct 2021
Published: Mon 13, Dec 2021
Copyright
© 2023 Lei Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.DOI: 10.31487/j.JICOA.2021.04.03
Author Info
Chengfen Yin Jianguo Li Zhiyong Wang Yongle Zhi Lei Xu
Corresponding Author
Lei XuDepartment of Critical Care Medicine, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China
Figures & Tables
Get access to the full version of this article.
References
1. World Health
Organization. Coronavirus disease (COVID-19) outbreak.
2. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic.
3. Jiang F, Deng L,
Zhang L, Cai Y, Cheung CW et al. (2020) Review of the Clinical Characteristics
of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 35: 1545-1549.
[Crossref]
4. Huang C, Wang Y, Li
X, Ren L, Zhao J et al. (2020) Clinical features of patients infected with 2019
novel coronavirus in Wuhan, China. Lancet 395: 497-506. [Crossref]
5. Liu C, Jiang ZC,
Shao CX, Zhang HG, Yue HM et al. (2020) Preliminary study of the relationship
between novel coronavirus pneumonia and liver function damage: a multicenter
study. Zhonghua Gan Zang Bing Za Zhi 28: 107-111. [Crossref]
6. Zheng YY, Ma YT,
Zhang JY, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev
Cardiol 17: 259-260. [Crossref]
7. https://news.youth.cn/jsxw/202002/t20200205_12186073.htm.
8. Jensen MM, Kellett
JG, Hallas P, Brabrand M (2019) Fever increases heart rate and respiratory
rate; a prospective observational study of acutely admitted medical patients. Acute
Med 18: 141-143. [Crossref]
9. Turner AJ, Hiscox
JA, Hooper NM (2004) ACE2: from vasopeptidase to SARS virus receptor. Trends
Pharmacol Sci 25: 291-294. [Crossref]
10. Wong CK, Lam CW, Wu
AK, WK Ip, Lee NLS et al. (2004) Plasma inflammatory cytokines and chemokines
in severe acute respiratory syndrome. Clin Exp Immunol 136: 95-103. [Crossref]
11. Chan JF, Yuan S,
Kok KH, To KKW, Chu H et al. (2020) A familial cluster of pneumonia associated
with the 2019 novel coronavirus indicating person-to-person transmission: a
study of a family cluster. Lancet 395: 514-523. [Crossref]
12. Cygankiewicz I,
Zareba W (2013) Heart rate variability, Handb Clin Neurol 117: 379-393.
[Crossref]
13. Apaioannou VE, Verkerk
AO, Amin AS, de Bakker JMT (2013) Intracardiac origin of heart rate
variability, pacemaker funny current and their possible association with
critical illness. Curr Cardiol Rev 9: 82-96. [Crossref]
14. Seely AJE, Christou
NV (2000) Multiple organ dysfunction syndrome: exploring the paradigm of
complex nonlinear systems. Crit Care Med 28: 2193-2200. [Crossref]
15. Akselrod S, Gordon
D, Ubel FA, Shannon DC, Berger AC et al. (1981) Power spectrum analysis of
heart rate fluctuation: a quantitative probe of beat to beat cardiovascular
control. Science 213: 220-222. [Crossref]
16. Goldberger AL,
Amaral LAN, Hausdorff JM, Ivanov PC, Peng CK et al. (2002) Fractal dynamics in
physiology: alterations with disease and aging. Proc Natl Acad Sci USA
99: 2466-2472. [Crossref]
17. Godin PJ, Buchman
TG (1996) Uncoupling of biological oscillators: A complementary hypothesis
concerning the pathogenesis of multiple organ dysfunction syndrome. Crit
Care Med 24: 1107-1116. [Crossref]
18. Griffin MP, Lake
DE, Bissonette EA, Harrell Jr FE, O'Shea TM et al. (2005) Heart rate
characteristics: novel physiomarkers to predict neonatal infection and death. Pediatrics
116: 1070-1074. [Crossref]
19. Zaza A, Lombardi F
(2001) Autonomic indexes based on the analysis of heart rate variability: a
view from the sinus node. Cardiovsc Res 50: 434-442. [Crossref]
20. H Lu (2020) Drug
treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends
14: 69-71. [Crossref]
21. Lebech AM,
Kristoffersen US, Mehlsen J, Wiinberg N, Petersen CL et al. (2007) Autonomic
dysfunction in HIV patients on antiretroviral therapy: studies of heart rate
variability. Clin Physiol Funct Imaging 27: 363-367. [Crossref]
22. Askgaard G,
Kristoffersen US, Mehlsen J, Kronborg G, Kjaer A et al. (2011) Decreased heart
rate variability in HIV positive patients receiving antiretroviral therapy:
Importance of blood glucose and cholesterol. PLoS One 6: e20196. [Crossref]
23. Dalakas MC (2001)
Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6:
14-20. [Crossref]
24. Peltier AC, Russell
JW (2002) Recent advances in drug-induced neuropathies. Curr Opin Neurol
15: 633-638. [Crossref]
25. Authier FJ, Gheradi
RK (2003) Peripheral neuropathies in HIV-infected patients in the era of HAART.
Brain Pathol 13: 223-228. [Crossref]
26. Licht CM, Vreeburg SA, van Reedt Dortland AK, Giltay EJ, Hoogendijk WJG et al. (2010) Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab 95: 2458-2466. [Crossref]
27. Sakabe M, Yoshioka R, Fujiki A (2013) Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J Cardiol Cases 8: 173-175. [Crossref]